

COMPOUND DESCRIPTION	<p>Axitinib is an oral selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3.</p> <p>Axitinib is an investigational agent and has not yet been approved by regulatory agencies.</p>
ABOUT VEGF RECEPTORS	<p>VEGFR are thought to play a role in the growth and spread of many tumors, including renal cell carcinoma, breast, lung, thyroid and colorectal cancer.¹</p> <p>VEGFR 1, 2 and 3 are located on the surface of the endothelial cells.¹</p> <p>Inhibition of the VEGFR 1, 2 and 3 is thought to induce tumor regression by impacting the tumor in various ways:</p> <ul style="list-style-type: none"> • Inhibition of VEGFR 1 prevents the VEGF ligand from binding and inducing tumor vascularization • Signaling through VEGFR 2 promotes endothelial cell proliferation, a major driver of angiogenesis (the growth of new blood vessels) • VEGFR 3 pathway signaling is believed to mediate lymphangiogenesis (the growth of lymphatic vessels) and is associated with the spreading of tumor cells to regional lymph nodes in certain tumors which can prevent distant metastasis
CLINICAL STUDIES	<p>Axitinib is being studied as both a single agent and in combination across many tumor types. Following is a list of some of the axitinib trials that are currently open and enrolling:</p> <p><u>Renal Cell Carcinoma (RCC)</u></p> <p>Phase 3</p> <ul style="list-style-type: none"> • AGILE 1032 (also known as the AXIS trial) – Randomized, open-label efficacy and safety study of axitinib versus sorafenib in previously treated metastatic RCC² <p><u>Non-Small Cell Lung Cancer</u></p> <p>Phase 2</p> <ul style="list-style-type: none"> • AGILE 1039 - Randomized, open-label efficacy and safety study of axitinib with cisplatin/pemetrexed vs cisplatin/pemetrexed alone in patients with nonsquamous NSCLC³

For more information, please visit www.pfizeroncology.com or www.clinicaltrials.gov or call toll-free 1-877-369-9753 (in the United States and Canada) or +1-646-277-4066 (outside of the United States and Canada).

For additional information, please visit: <http://www.pfizer.com/asco>.

¹ Hicklin DJ, Ellis LM. Role of VEGF in Tumor Growth and Angiogenesis. *JCO*. 2007;23:1011-1027.

² ClinicalTrials.gov. Axitinib (Ag 013736) As Second Line Therapy for Metastatic Renal Cell Cancer. Available at: <http://www.clinicaltrials.gov/ct2/show/NCT00678392?term=axitinib&rank=1>. Accessed: May 14, 2009.

³ ClinicalTrials.gov. Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer. Available at:

<http://www.clinicaltrials.gov/ct2/show/NCT00768755?term=axitinib&rank=2>. Accessed May 14, 2009.

For additional information, please visit: <http://www.pfizer.com/asco>.